Abcuro said it is adding $66 million to re-enter development in inclusion body myositis, a rare inflammatory disorder with no approved disease-modifying therapies. The company plans a new study intended to support a biologics license application. Abcuro previously ran a Phase 2/3 program that failed earlier this year, but management pointed to positive trends among patients with less severe disease. The restart highlights how patient subgroups and endpoint strategy can determine whether programs advance after setbacks. For investors and clinicians, the announcement spotlights the risk-reward profile of rare-disease immunology—where smaller cohorts, heterogeneous disease biology, and trial design choices frequently drive outcomes.